Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox – European Update

Feb 7, 2017Cathy WilsonNews

7 February 2017

ASX ANNOUNCEMENT

Penthrox: European update

Medical Developments International Limited (ASX: MVP) provides the following update on its Penthrox business in Europe.

United Kingdom and Ireland

In the United Kingdom and Ireland, Galen continue to make good progress in rolling out Penthrox.  34 Hospitals have approved and are now using Penthrox.  There are 11 major trauma center hospitals in the UK, four of which have approved and are using Penthrox.

For details relating to the full ASX release, please click on the following link: ASX Announcement – Penthrox European Update – 7 Feb 2017

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Penthrox Marketing Authorisation Application in Russia

    6 December 2019 ASX ANNOU...

  • Penthrox IND approved in China

    21 November 2019 ASX ANNO...

  • MVP signs new Manufacturing Development Project with CSIRO

    29 October 2019 ASX ANNOU...

Healthcare Professional Registration

Login to access healthcare professional resources


Remember Me

Forgot password? | Register

Medical Developments International

Address: 4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:
Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.